Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
Blood oxygenation level-dependent (BOLD) contrast magnetic resonance imaging (MRI) for prediction of breast cancer chemotherapy response: A pilot study
Lan Jiang; Paul T. Weatherall; Roderick W. McColl; Debu Tripathy; Ralph P. Mason(Profiled Authors: Lan Jiang; Ralph P Mason; Roderick W McColl; Paul T Weatherall)
Journal of Magnetic Resonance Imaging. 2013;37(5):1083-1092.Abstract
Purpose: To determine whether a simple noninvasive method of assessing tumor oxygenation is feasible in the clinical setting and can provide useful, potentially predictive information. Tumor microcirculation and oxygenation play critical roles in tumor growth and responsiveness to cytotoxic treatment and may provide prognostic indicators for cancer therapy. Deoxyhemoglobin is paramagnetic and can serve as an endogenous contrast agent causing signal loss in echo planar magnetic resonance imaging (MRI) (blood oxygenation level-dependent [BOLD]-MRI). We used BOLD-MRI to provide early evaluation of response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Materials and Methods: MRI was performed on 11 patients with biopsy-proven malignancy. MRI exams were scheduled before, during, and after chemotherapy. The BOLD study applied a 6-minute oxygen breathing challenge. Results: Seven patients successfully completed the exams. Before chemotherapy, BOLD contrast enhancement was observed in all tumors, but the patients, who ultimately had complete pathological response, exhibited a significantly higher BOLD response to oxygen breathing. Conclusion: We have successfully implemented an oxygen-breathing challenge BOLD contrast technique as part of the standard breast MRI exam in patients with locally advanced breast cancer. The preliminary observation that a large BOLD response correlated with better treatment response suggests a predictive capability for BOLD MRI. © 2012 Wiley Periodicals, Inc.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
André Robidoux; Gong Tang; Priya Rastogi; Charles E Geyer; Catherine A Azar; James N Atkins; Louis Fehrenbacher; Harry D Bear; Louis Baez-Diaz; Shakir Sarwar; et al.The Lancet Oncology. 2013;14(12):1183-1192.
Edith A. Perez; Edward H. Romond; Vera J. Suman; Jong-Hyeon Jeong; Nancy E. Davidson; Charles E. Geyer Jr.; Silvana Martino; Eleftherios P. Mamounas; Peter A. Kaufman; Norman WolmarkJournal of Clinical Oncology. 2011;29(25):3366-3373.
Aman U Buzdar; Vera J Suman; Funda Meric-Bernstam; A Marilyn Leitch; Matthew J Ellis; Judy C Boughey; Gary Unzeitig; Melanie Royce; Linda M McCall; Michael S Ewer; et al.
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): A randomised, controlled, phase 3 trialThe Lancet Oncology. 2013;14(13):1317-1325.
Appears in this Document